Breast Cancer
Conference Coverage
First report from NeoTRIPaPDL1: No pCR benefit with atezolizumab in TNBC
SAN ANTONIO – Adding atezolizumab, an anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, to neoadjuvant...
Conference Coverage
ctDNA, CTCs predict TNBC relapse – now what?
SAN ANTONIO – Liquid biopsy can identify patients with triple-negative breast cancer at high risk of relapse, but no...
Conference Coverage
CTS5 score partially validated for predicting late distant breast cancer recurrences
SAN ANTONIO – The CTS5 prognostic score is strongly predictive of risk of late distant recurrence of breast cancer in patients over age 50 at...
Conference Coverage
Residual cancer burden linked to long-term survival
SAN ANTONIO – Results from large meta-analysis are expected to alter the American Joint Committee on Cancer (AJCC) staging standards in breast...
Conference Coverage
TNBC: Adding capecitabine boosts disease-free survival in prospective trial
SAN ANTONIO - In a phase 3 trial of 585 women with triple-negative breast cancer, 5-year disease free survival was 86.26% in the capecitabine...
Conference Coverage
Pembrolizumab plus chemo boosts pCR rate in TNBC
SAN ANTONIO – The immune checkpoint inhibitor added to standard chemotherapy increased the likelihood of a pathologic complete remission,...
Conference Coverage
Promising new neoadjuvant strategy in luminal B breast cancer
SAN ANTONIO – Combining a CDK4/6 inhibitor with an aromatase inhibitor successfully downstages disease before surgery.
Conference Coverage
APHINITY 6-year data: Benefit ongoing in HER2+ early BC, no significant OS benefit
Adding adjuvant pertuzumab to trastuzumab plus chemotherapy for HER2+ early breast cancer shows ongoing benefit vs. placebo at 6 years in the...
Conference Coverage
Ten-year results support partial breast irradiation
SAN ANTONIO – There was no statistically significant difference in 10-year ipsilateral breast tumor recurrence between those who received...
Conference Coverage
Capecitabine extends survival in triple-negative breast cancer
In a meta-analysis of data on more than 15,000 patients with early-stage breast cancer, adding capecitabine to systemic treatment resulted in a 22...
Conference Coverage
Tucatinib called game-changer in HER2-positive metastatic breast cancer
SAN ANTONIO – In the HER2CLIMB trial of women with heavily pretreated HER2-positive metastatic breast cancer, the 2-year estimated overall...